FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Picchio Gaston 2. Issuer Name and Ticker or Trading Symbol Arbutus Biopharma Corp [ ABUS ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Development Officer
(Last)         (First)         (Middle)
C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE
3. Date of Earliest Transaction (MM/DD/YYYY)
9/23/2020
(Street)
WARMINSTER, PA 18974
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock  $3.35 (1) 9/23/2020    A     50000       (2) 2/17/2020  Common Stock  50000.0  $0  50000  D   

Explanation of Responses:
(1)  Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on February 14, 2020, the trading day immediately preceding the date the performance based option grant wasapproved by the Executive Compensation and Human Resources Committee of the Board of Directors (the "Committee") of Arbutus Biopharma Corporation, subject to both shareholder approval of anamendment to the Registrant's 2016 Omnibus Share and Incentive Plan (the "Plan Amendment") and the fulfillment of certain performance criteria.
(2)  The Registrant's shareholders approved the Plan Amendment on May 28, 2020. On September 23, 2020, the Committee determined that the performance criteria had been met.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Picchio Gaston
C/O ARBUTUS BIOPHARMA CORPORATION
701 VETERANS CIRCLE
WARMINSTER, PA 18974


Chief Development Officer

Signatures
/s/ David C. Hastings as attorney-in-fact for Gaston Picchio 9/25/2020
**Signature of Reporting Person Date
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Dec 2020 to Jan 2021 Click Here for more Arbutus Biopharma Charts.
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Jan 2020 to Jan 2021 Click Here for more Arbutus Biopharma Charts.